Video - Results from #10

Artificial Intelligence in Prostate Cancer VL

Search

Artera Multi-Modal AI Platform - Guiding Treatment Decisions in Men with Prostate Cancer - Andre Esteva & Felix Feng Details Andre Esteva and Felix Feng join Alicia Morgans to discuss the Artera MMAI platform in prostate cancer intended to identify patients who will benefit from therapy intensification and help guide treatment decisions for men with high-risk localized prostate cancer. Artera has developed a unique multi-modal artificial intelligence (MMAI) algorithm composed of two pieces. One piece learns from imagery...
Beyond the NCCN Localized Prostate Cancer Risk Category: The MMAI Prognostic Risk Stratification Model - Jonathan Tward Details Jonathan Tward joins Alicia Morgans to discuss advancing prognostic capabilities in prostate cancer risk stratification using multimodal deep learning with digital histopathology within the context of a series of NRG Oncology phase III trials. The Artera AI prognostic biomarker model is based on five prospectively randomized trials of over 5,500 patients with low-risk prostate cancer on radiation...
Multi-Modal Artificial Intelligence (MMAI) Prognostic Biomarker in High-Risk Prostate Cancer - Daniel Spratt Details Alicia Morgans and Daniel Spratt discuss an AI-derived multi-modal digital pathology-based biomarker test designed towards improving risk stratification in high risk prostate cancer and then supporting personalized treatment decisions in these men. Biographies: Daniel Spratt, MD, Chair, Department of Radiation Oncology, UH Cleveland Medical Center Professor, CWRU School of Medicine, Cleveland, OH...
Artificial Intelligence Transformative in Prostate Cancer Patient Care - Felix Feng Details Felix Feng joins Alicia Morgans to discuss how the application of artificial intelligence (AI) is transformative in prostate cancer care. Dr. Feng focuses on how AI will assist physicians in their goal to personalize treatment for every individual patient. Dr. Feng explains how AI is currently used as a prognostic tool in the identification of recurrence rates for patients, or identifying the rate...
Who is ARTERA? - Andre Esteva Details Andre Esteva, CEO of Artera Inc joins Alicia Morgans in a discussion about Artera, which has developed an artificial intelligence-derived digital pathology-based biomarker test for prostate cancer that enables prostate cancer personalized therapy. It is intended to identify patients that will benefit from therapy intensification and to help guide treatment decisions for men with localized intermed...
Beyond Genomics: AI Informing Decision Making in Prostate Cancer – Ashley Ross Details In this conversation, Alicia Morgans and Ashley Ross discuss the current clinical landscape of how risk is defined in localized prostate cancer highlighting a novel artificial intelligence (AI) derived digital pathology-based biomarker test for prostate cancer, Artera. Artera AI is a multi-modal algorithm intended to identify patients that will benefit from therapy intensification and to help guid...